Product image of Nilotinib Mylan (Nilotinib) supplied by GNH India

Nilotinib Mylan

Active Ingredient:
Nilotinib
Origin:
EU

Nilotinib Mylan (Nilotinib)

Nilotinib, the active ingredient in Nilotinib Mylan, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It selectively blocks the BCR‑ABL enzyme, thereby treating chronic myeloid leukemia in the chronic phase and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH India supplies Nilotinib Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable access to high‑quality oncology medicines.

Manufacturer / TM Owner

Viatris Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nilotinib is indicated for hematologic malignancies driven by the BCR‑ABL tyrosine kinase.

  • Chronic myeloid leukemia (CML): reduces disease progression and improves survival in patients in the chronic phase.
  • CML (accelerated or blast phase): offers a therapeutic option when resistance to prior tyrosine‑kinase inhibitors occurs.
  • Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission induction in adult patients.

How It Works

  • Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase by binding to its ATP‑binding site, preventing downstream signaling that drives leukemic cell proliferation and survival. This blockade also affects related kinases such as KIT and PDGFR, contributing to its antineoplastic activity in BCR‑ABL‑positive malignancies.

Side Effects

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate upset stomach.
  • Diarrhea: loose stools, often transient.
  • Rash: skin erythema or pruritus.
  • Fatigue: generalized tiredness.
  • Headache: mild to moderate intensity.
  • Myalgia: muscle aches.

Serious or Rare Side Effects

  • QT interval prolongation: may lead to cardiac arrhythmias.
  • Pancreatitis: inflammation of the pancreas, presenting with abdominal pain.
  • Hepatic toxicity: elevated liver enzymes or hepatitis.
  • Severe neutropenia: marked reduction in neutrophil count.
  • Severe thrombocytopenia: low platelet levels increasing bleeding risk.
  • Anaphylactic reactions: rare but potentially life‑threatening hypersensitivity.

Precautions & Warnings

Before initiating therapy, clinicians should assess several safety parameters.

  • Cardiac monitoring: obtain baseline ECG and periodically evaluate QT interval.
  • Hepatic function: monitor liver enzymes regularly during treatment.
  • Pancreatic enzymes: check amylase and lipase to detect pancreatitis early.
  • Pregnancy: avoid use; safety in pregnancy and lactation is unknown.
  • Drug interactions: review concomitant QT‑prolonging or CYP3A4‑modulating agents.
  • Store below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Nilotinib has a notable interaction profile that requires careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Nilotinib exposure.
  • QT‑prolonging drugs (e.g., amiodarone, sotalol): additive risk of cardiac arrhythmias.
  • Antacids containing aluminum or magnesium: can reduce absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower Nilotinib levels.
  • Warfarin: potential alteration of anticoagulant effect, requiring INR monitoring.
  • Statins metabolized by CYP3A4 (e.g., simvastatin): increased risk of statin‑related toxicity.
  • Diuretics causing electrolyte imbalance: may exacerbate QT prolongation.

Frequently Asked Questions

Nilotinib Mylan is prescribed for patients with chronic myeloid leukemia in the chronic phase and for adults with Philadelphia chromosome‑positive acute lymphoblastic leukemia. Both conditions are driven by the BCR‑ABL fusion protein, and Nilotinib targets this abnormal kinase to control disease progression.

Nilotinib binds selectively to the ATP‑binding pocket of the BCR‑ABL tyrosine kinase, blocking its activity. This inhibition stops downstream signaling pathways that promote leukemic cell growth and survival, leading to reduced proliferation of malignant cells in BCR‑ABL‑positive cancers.

The specific dose of Nilotinib Mylan is determined by the treating physician based on the patient’s disease status, prior therapies, and individual health factors. Prescribers follow established clinical guidelines and adjust the regimen as needed for safety and efficacy.

Safety of Nilotinib in pregnancy and lactation has not been established. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk, and alternative therapies should be considered whenever possible.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor offering higher potency and selectivity compared with first‑generation agents such as imatinib. It is often used when patients exhibit resistance or intolerance to earlier TKIs, though each agent has a distinct safety and interaction profile that guides therapeutic choice.

Nilotinib Mylan tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Maintaining these conditions helps preserve the product’s stability and potency throughout its shelf life.

Nilotinib Mylan is taken orally, usually as whole tablets with a moderate‑fat meal to enhance absorption. Patients should follow the prescribing physician’s instructions regarding timing, food intake, and any necessary dose adjustments.

The most serious risks include QT interval prolongation, which can lead to potentially fatal arrhythmias, severe hepatic toxicity, pancreatitis, and profound reductions in blood cell counts such as neutropenia or thrombocytopenia. Regular monitoring of cardiac, liver, and pancreatic parameters is essential to mitigate these risks.

Patients with a known hypersensitivity to Nilotinib or any of its excipients should avoid the drug. It is also contraindicated in individuals with a history of significant QT prolongation, uncontrolled cardiac disease, or severe hepatic impairment, unless a specialist determines that benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nilotinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT